2024 MIIF China: Bridging the Present and Future of Laboratory Diagnostics

The MIIF, debuted in 2011, has brought together over one thousand laboratory experts from more than one hundred countries to exchange the latest knowledge and best practices in laboratory diagnostics. This year, at 2024 MIIF China on April 23-24, jointly organized by IFCC, EFLM, SIBioC, and Mindray, over two hundred laboratory professionals from around the world have gathered to explore the latest advancements and upcoming trends in the field. Covering a diverse range of topics from novel biomarkers to cutting-edge diagnostic technologies, the forum provides a peek into the future landscape of the industry through insightful discussions.

At the opening ceremony, Senior Vice President of Mindray, Mr. Li Zaiwen, delivered a speech emphasizing the significance of global exchange and collaboration among laboratory professionals in driving the progress of laboratory medicine.

The academic forum has showcased brilliant ideas, with experts from industry associations such as IFCC, EFLM, and SIBioC, as well as renowned universities, presenting their insights and latest research findings on various topics. These topics include new cardiac biomarkers, digital morphology, and laboratory development and accreditation. During their presentation of research studies, the speakers noted the superior performance of Mindray's products and their clinical value in early disease diagnosis, specifically highlighting the high-sensitive troponin I, digital morphology and SF Cube technology, all supported by evaluation data. They also pointed out the innovative technology implemented in Mindray solutions, contributing to improved laboratory efficiency and productivity.

At the Roundtable Discussion themed "Innovation at Heart", experts discussed the clinical value of cardiac biomarkers such as the high-sensitive troponin I and future perspectives on novel cardiac marker research. Dr. He Jianwen, Chief Scientist of Mindray In-Vitro Diagnostics, highlighted Mindray's close integration with clinical settings, rigorous validation of clinical applications, and continuous innovation to meet growing demands. The recent launch of the high-sensitive troponin I, endorsed by top experts globally, demonstrates Mindray's latest achievement in addressing clinical challenges in cardiovascular disease.